Company profile
RECURSION PHARMACEUTICALS, INC.
NASDAQ:RXRXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| REC-2282 | phase2_3 | — | 1 | terminated |
| TAK-733 | phase1 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06678659 | phase1_2 | recruiting | 2024-11-21 | 2028-10-30 | Recursion Pharmaceuticals Inc. | A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer |
| NCT06005974 | phase2 | terminated | 2024-01-15 | 2025-02-24 | Recursion Pharmaceuticals Inc. | A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation |
| NCT06980116 | phase1 | recruiting | 2025-03-31 | 2028-06-01 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies |
| NCT07517198 | phase1 | recruiting | 2026-04-13 | 2029-03-01 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors |
| NCT05130866 | phase2_3 | terminated | 2022-06-20 | 2025-08-18 | Recursion Pharmaceuticals Inc. | Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas |
FDA applications (0)
No records yet.